Xingaotuo Biotechnology
AAV-mediated gene therapy restoring congenital hearing loss
About Xingaotuo Biotechnology
Xingaotuo Biotechnology, also known as Otovia Therapeutics, is a clinical-stage biotechnology company focused on developing gene therapies for genetic hearing loss. The company's primary area of research is the treatment of autosomal recessive deafness 9 (DFNB9), which is caused by mutations in the OTOFERLIN (OTOF) gene. This mutation prevents the production of the otoferlin protein, which is critical for transmitting sound signals from the inner ear to the brain.
The company's main product is an adeno-associated virus (AAV)-mediated gene therapy designed to deliver a healthy copy of the OTOF gene to the inner ear's cochlea. Due to the large size of the OTOF gene, the therapy utilizes a dual-vector approach, splitting the gene into two parts, which are then delivered via two separate AAVs. This treatment is administered via a direct injection into the fluid-filled cochlea. Clinical trials have shown promising results, with patients demonstrating significant hearing improvement within a month of treatment. In some cases, hearing has been restored to the normal range, allowing children who were previously deaf to hear conversational sounds and recognize speech.
Collaborating with institutions like Southeast University, the company has conducted clinical trials that have demonstrated both the safety and efficacy of their AAV-OTOF therapy in human patients. The research has progressed from successful preclinical studies in mice and non-human primates to treating children as young as 10 months old. More than 90% of children treated in the OTOF-based gene therapy trials have shown improved auditory skills. This work is considered a significant advancement, providing a proof-of-concept that may open the door for developing treatments for other forms of genetic deafness.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Neurology, Genetics and genomics, Pediatrics, Gene Therapy, Rare Diseases, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jan 2026 | $14M | $55M | Nanjing Innovation Capital · Fosun Health Capital · Dingxin Capital | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xingaotuo Biotechnology in its local ecosystem
The Xingaotuo Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- NCNanjing Innovation Capital
- FCFosun Health Capital
- DCDingxin Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xingaotuo Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xingaotuo Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









